Transcriptomics

Dataset Information

0

Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa


ABSTRACT: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin disease characterized by defects in type VII collagen leading to a range of fibrotic pathologies resulting from skin fragility, aberrant wound healing and altered dermal fibroblast physiology. Using a novel in vitro model of fibrosis based on endogenously produced extracellular matrix, we screened an FDA-approved compound library and identified antivirals as a class of drug not previously associated with anti-fibrotic action. Pre-clinical validation of our lead hit, daclatasvir, in a mouse model of RDEB demonstrated significant improvement in fibrosis as well as overall quality of life with increased survival, weight gain and activity, and a decrease in pruritus-induced hair loss. Immunohistochemical assessment of daclatasvir-treated RDEB mouse skin showed a reduction in fibrotic markers, which was supported by in vitro data demonstrating TGFβ pathway targeting and a reduction of total collagen retained in the extracellular matrix. Our data support clinical development of antivirals for treatment of patients with RDEB and potentially other fibrotic diseases.

ORGANISM(S): Homo sapiens

PROVIDER: GSE254347 | GEO | 2024/03/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-09-02 | GSE239569 | GEO
2012-05-15 | E-GEOD-37738 | biostudies-arrayexpress
2012-05-16 | GSE37738 | GEO
2014-04-03 | E-GEOD-51056 | biostudies-arrayexpress
2014-04-03 | GSE51056 | GEO
2024-08-31 | PXD047998 | Pride
2022-03-16 | GSE181357 | GEO
2021-12-30 | GSE171405 | GEO
2020-04-22 | GSE130925 | GEO
2024-02-17 | GSE236849 | GEO